Results of the cooperative protocol (N-III-95) for metastatic relapses and refractory neuroblastoma.
BACKGROUND
Prognosis of relapsed and refractory neuroblastoma is uniformly fatal; new therapeutic approaches are needed.


METHODS
Relapsed and refractory neuroblastoma patients were treated with continuous infusion chemotherapy combined with MIBG.


RESULTS
Over 4 years, 35 heavily pretreated patients were registered, 29 with bone or/and bone marrow metastases. Grade 3 or 4 hematologic toxicity was frequent, without toxic deaths. Sixteen patients responded. The probability of 5-year overall survival was 0.19.


CONCLUSIONS
This approach is feasible and toxicity manageable; it rescued some patients and prolonged their survival. It merits assay in newly diagnosed high-risk neuroblastoma patients.
Castel
V
V
Unidad de Oncología Pediátrica, Hospital Infantil La Fe, Valencia, Spain.
Cañete
A
A
Melero
C
C
Acha
T
T
Navajas
A
A
García-Miguel
P
P
Contra
T
T
Molina
J
J
Galarón
P
P
Cruz
O
O
D019797:3-Iodobenzylguanidine / Q000627:therapeutic use*; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009447:Neuroblastoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary*; D015996:Survival Rate
D019797:3-Iodobenzylguanidine